Immunotherapy in colorectal cancer: What have we learned so far?

Clinica Chimica Acta

Volumn 460, Issue , 2016, Pages 78-87

  Sanchez Castañón, María ^a   Er, Tze Kiong ^b   Bujanda, Luis ^c   Herreros Villanueva, Marta ^c,d  

^a HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

^b ASIA UNIVERSITY   (Taiwan)

^c HOSPITAL DONOSTIA   (Spain)

^d Mayo Clinic College of Medicine   (United States)

Author keywords

Antibodies; Antigens; Colorectal cancer; Immunotherapy; Vaccines

Indexed keywords

AMP 224; ANTINEOPLASTIC AGENT; BMS 936559; CANCER VACCINE; CYTOKINE; DENDRITIC CELL VACCINE; DURVALUMAB; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PEPTIDE VACCINE; RECOMBINANT INTERLEUKIN 10; TUMOR CELL VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ADOPTIVE TRANSFER; ANTIBODY RESPONSE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CANCER STEM CELL; CELL BASED IMMUNOTHERAPY; CHIMERIC ANTIGEN RECEPTOR T CELL; CLINICAL TRIAL (TOPIC); COLORECTAL CANCER; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOTHERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; COLORECTAL NEOPLASMS; PERSONALIZED MEDICINE; PROCEDURES;

CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; IMMUNOTHERAPY; PRECISION MEDICINE;

EID: 84976557573     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2016.06.027     Document Type: Review

References (85)

1. [1] Cunningham, D., Atkin, W., Lenz, H.J., Lynch, H.T., Minsky, B., Nordlinger, B., Starling, N., Colorectal cancer. Lancet 375:9719 (2010), 1030–1047.
2. [2] Van Cutsem, E., Nordlinger, B., Adam, R., Kohne, C.H., Pozzo, C., Poston, G., Ychou, M., Rougier, P., Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Eur. J. Cancer 42:14 (2006), 2212–2221.
3. [3] Gallagher, D.J., Kemeny, N., Metastatic colorectal cancer: from improved survival to potential cure. Oncology 78:3–4 (2010), 237–248.
4. [4] Teng, M.W., Swann, J.B., Koebel, C.M., Schreiber, R.D., Smyth, M.J., Immune-mediated dormancy: an equilibrium with cancer. J. Leukoc. Biol. 84:4 (2008), 988–993.
5. [5] Dunn, G.P., Old, L.J., Schreiber, R.D., The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21:2 (2004), 137–148.
6. [6] Pernot, S., Terme, M., Voron, T., Colussi, O., Marcheteau, E., Tartour, E., Taieb, J., Colorectal cancer and immunity: what we know and perspectives. World J. Gastroenterol. 20:14 (2014), 3738–3750.
7. [7] Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M.A., Vallejo, C., Martos, J.A., Moreno, M., The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79:12 (1997), 2320–2328.
8. [8] Sandel, M.H., Speetjens, F.M., Menon, A.G., Albertsson, P.A., Basse, P.H., Hokland, M., Nagelkerke, J.F., Tollenaar, R.A., van de Velde, C.J., Kuppen, P.J., Natural killer cells infiltrating colorectal cancer and MHC class I expression. Mol. Immunol. 42:4 (2005), 541–546.
9. [9] Tachibana, T., Onodera, H., Tsuruyama, T., Mori, A., Nagayama, S., Hiai, H., Imamura, M., Increased intratumor Valpha24-positive natural killer T cells: a prognostic factor for primary colorectal carcinomas. Clin. Cancer Res. 11:20 (2005), 7322–7327.
10. [10] Corvaisier, M., Moreau-Aubry, A., Diez, E., Bennouna, J., Mosnier, J.F., Scotet, E., Bonneville, M., Jotereau, F., V gamma 9V delta 2 T cell response to colon carcinoma cells. J. Immunol. 175:8 (2005), 5481–5488.
11. [11] Pages, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353:25 (2005), 2654–2666.
12. [12] Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pages, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313:5795 (2006), 1960–1964.
13. [13] Fauquembergue, E., Toutirais, O., Tougeron, D., Drouet, A., Le Gallo, M., Desille, M., Cabillic, F., de La Pintiere, C.T., Iero, M., Rivoltini, L., et al. HLA-A*0201-restricted CEA-derived peptide CAP1 is not a suitable target for T-cell-based immunotherapy. J. Immunother. 33:4 (2010), 402–413.
14. [14] Smyrk, T.C., Watson, P., Kaul, K., Lynch, H.T., Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer 91:12 (2001), 2417–2422.
15. [15] Michael-Robinson, J.M., Biemer-Huttmann, A., Purdie, D.M., Walsh, M.D., Simms, L.A., Biden, K.G., Young, J.P., Leggett, B.A., Jass, J.R., Radford-Smith, G.L., Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status. Gut 48:3 (2001), 360–366.
16. [16] Benatti, P., Gafa, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., Maestri, I., Guerzoni, L., Roncucci, L., Menigatti, M., et al. Microsatellite instability and colorectal cancer prognosis. Clin. Cancer Res. 11:23 (2005), 8332–8340.
17. [17] Saeterdal, I., Gjertsen, M.K., Straten, P., Eriksen, J.A., Gaudernack, G., A TGF betaRII frameshift-mutation-derived CTL epitope recognised by HLA-A2-restricted CD8 + T cells. Cancer Immunol. Immunother. 50:9 (2001), 469–476.
18. [18] Menon, A.G., Morreau, H., Tollenaar, R.A., Alphenaar, E., Van Puijenbroek, M., Putter, H., Janssen-Van Rhijn, C.M., Van De Velde, C.J., Fleuren, G.J., Kuppen, P.J., Down-regulation of HLA-A expression correlates with a better prognosis in colorectal cancer patients. Lab. Investig. 82:12 (2002), 1725–1733.
19. [19] Watson, N.F., Ramage, J.M., Madjd, Z., Spendlove, I., Ellis, I.O., Scholefield, J.H., Durrant, L.G., Immunosurveillance is active in colorectal cancer as downregulation but not complete loss of MHC class I expression correlates with a poor prognosis. Int. J. Cancer 118:1 (2006), 6–10.
20. [20] Salama, P., Phillips, M., Grieu, F., Morris, M., Zeps, N., Joseph, D., Platell, C., Iacopetta, B., Tumor-infiltrating FOXP3 + T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27:2 (2009), 186–192.
21. [21] Chaput, N., Louafi, S., Bardier, A., Charlotte, F., Vaillant, J.C., Menegaux, F., Rosenzwajg, M., Lemoine, F., Klatzmann, D., Taieb, J., Identification of CD8 + CD25 + Foxp3 + suppressive T cells in colorectal cancer tissue. Gut 58:4 (2009), 520–529.
22. [22] Bonertz, A., Weitz, J., Pietsch, D.H., Rahbari, N.N., Schlude, C., Ge, Y., Juenger, S., Vlodavsky, I., Khazaie, K., Jaeger, D., et al. Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J. Clin. Invest. 119:11 (2009), 3311–3321.
23. [23] Hua, D., Sun, J., Mao, Y., Chen, L.J., Wu, Y.Y., Zhang, X.G., B7-H1 expression is associated with expansion of regulatory T cells in colorectal carcinoma. World J. Gastroenterol. 18:9 (2012), 971–978.
24. [24] Bartnik, A., Nirmal, A.J., Yang, S.Y., Peptide vaccine therapy in colorectal cancer. Vaccine 1:1 (2012), 1–16 (Basel).
25. [25] Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F.M., Anichini, A., Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?. J. Natl. Cancer Inst. 94:11 (2002), 805–818.
26. [26] Gonzalez-Aparicio, M., Alzuguren, P., Mauleon, I., Medina-Echeverz, J., Hervas-Stubbs, S., Mancheno, U., Berraondo, P., Crettaz, J., Gonzalez-Aseguinolaza, G., Prieto, J., Hernandez-Alcoceba, R., Oxaliplatin in combination with liver-specific expression of interleukin 12 reduces the immunosuppressive microenvironment of tumours and eradicates metastatic colorectal cancer in mice., 60(3), 2011, 341–349.
27. [27] Tesniere, A., Schlemmer, F., Boige, V., Kepp, O., Martins, I., Ghiringhelli, F., Aymeric, L., Michaud, M., Apetoh, L., Barault, L., et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 29:4 (2010), 482–491.
28. [28] Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350:23 (2004), 2335–2342.
29. [29] Jocham, D., Richter, A., Hoffmann, L., Iwig, K., Fahlenkamp, D., Zakrzewski, G., Schmitt, E., Dannenberg, T., Lehmacher, W., von Wietersheim, J., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:9409 (2004), 594–599.
30. [30] Berd, D., Sato, T., Maguire, H.C. Jr., Kairys, J., Mastrangelo, M.J., Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine. J. Clin. Oncol. 22:3 (2004), 403–415.
31. [31] Klebanoff, C.A., Acquavella, N., Yu, Z., Restifo, N.P., Therapeutic cancer vaccines: are we there yet?. Immunol. Rev. 239:1 (2011), 27–44.
32. [32] Mosolits, S., Nilsson, B., Mellstedt, H., Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials. Expert Rev. Vaccines 4:3 (2005), 329–350.
33. [33] Restifo, N.P., Dudley, M.E., Rosenberg, S.A., Adoptive immunotherapy for cancer: harnessing the T cell response. Nat. Rev. Immunol. 12:4 (2012), 269–281.
34. [34] Koido, S., Hara, E., Homma, S., Torii, A., Toyama, Y., Kawahara, H., Watanabe, M., Yanaga, K., Fujise, K., Tajiri, H., et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11:21 (2005), 7891–7900.
35. [35] Koido, S., Hara, E., Torii, A., Homma, S., Toyama, Y., Kawahara, H., Ogawa, M., Watanabe, M., Yanaga, K., Fujise, K., et al. Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int. J. Cancer 117:4 (2005), 587–595.
36. [36] Goydos, J.S., Elder, E., Whiteside, T.L., Finn, O.J., Lotze, M.T., A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J. Surg. Res. 63:1 (1996), 298–304.
37. [37] Gonzalez, G., Crombet, T., Catala, M., Mirabal, V., Hernandez, J.C., Gonzalez, Y., Marinello, P., Guillen, G., Lage, A., A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann. Oncol. 9:4 (1998), 431–435.
38. [38] Miyagi, Y., Imai, N., Sasatomi, T., Yamada, A., Mine, T., Katagiri, K., Nakagawa, M., Muto, A., Okouchi, S., Isomoto, H., et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 7:12 (2001), 3950–3962.
39. [39] Moulton, H.M., Yoshihara, P.H., Mason, D.H., Iversen, P.L., Triozzi, P.L., Active specific immunotherapy with a beta-human chorionic gonadotropin peptide vaccine in patients with metasta. Clin. Cancer Res. 8:7 (2002), 2044–2051.
40. [40] Sugiyama, H., Cancer immunotherapy targeting Wilms' tumor gene WT1 product. Expert Rev. Vaccines 4:4 (2005), 503–512.
41. [41] Tsuruma, T., Hata, F., Torigoe, T., Furuhata, T., Idenoue, S., Kurotaki, T., Yamamoto, M., Yagihashi, A., Ohmura, T., Yamaguchi, K., et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Transl. Med., 2(1), 2004, 19.
42. [42] Sadanaga, N., Nagashima, H., Mashino, K., Tahara, K., Yamaguchi, H., Ohta, M., Fujie, T., Tanaka, F., Inoue, H., Takesako, K., et al. Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas. Clin. Cancer Res. 7:8 (2001), 2277–2284.
43. [43] Speetjens, F.M., Kuppen, P.J., Welters, M.J., Essahsah, F., Voet van den Brink, A.M., Lantrua, M.G., Valentijn, A.R., Oostendorp, J., Fathers, L.M., Nijman, H.W., et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15:3 (2009), 1086–1095.
44. [44] Paulsen, J.E., Bjorheim, J., Roe, J., Eide, T.J., Alexander, J., Gaudernack, G., Effect of vaccination with mutant KRAS peptides on rat colon carcinogenesis induced by azoxymethane. Anticancer Res. 22:1A (2002), 171–175.
45. [45] Schmoll, H.J., Wittig, B., Arnold, D., Riera-Knorrenschild, J., Nitsche, D., Kroening, H., Mayer, F., Andel, J., Ziebermayr, R., Scheithauer, W., Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial. J. Cancer Res. Clin. Oncol. 140:9 (2014), 1615–1624.
46. [46] Sinicrope, F.A., Rego, R.L., Ansell, S.M., Knutson, K.L., Foster, N.R., Sargent, D.J., Intraepithelial effector (CD3 +)/regulatory (FoxP3 +) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 137:4 (2009), 1270–1279.
47. [47] Marshall, J.L., Gulley, J.L., Arlen, P.M., Beetham, P.K., Tsang, K.Y., Slack, R., Hodge, J.W., Doren, S., Grosenbach, D.W., Hwang, J., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J. Clin. Oncol. 23:4 (2005), 720–731.
48. [48] Kaufman, H.L., Lenz, H.J., Marshall, J., Singh, D., Garett, C., Cripps, C., Moore, M., von Mehren, M., Dalfen, R., Heim, W.J., et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin. Cancer Res. 14:15 (2008), 4843–4849.
49. [49] Horig, H., Lee, D.S., Conkright, W., Divito, J., Hasson, H., LaMare, M., Rivera, A., Park, D., Tine, J., Guito, K., et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule. Cancer Immunol. Immunother. 49:9 (2000), 504–514.
50. [50] Celluzzi, C.M., Mayordomo, J.I., Storkus, W.J., Lotze, M.T., Falo, L.D. Jr., Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:1 (1996), 283–287.
51. [51] Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., Schadendorf, D., Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:3 (1998), 328–332.
52. [52] Berard, F., Blanco, P., Davoust, J., Neidhart-Berard, E.M., Nouri-Shirazi, M., Taquet, N., Rimoldi, D., Cerottini, J.C., Banchereau, J., Palucka, A.K., Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192:11 (2000), 1535–1544.
53. [53] Koido, S., Kashiwaba, M., Chen, D., Gendler, S., Kufe, D., Gong, J., Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165:10 (2000), 5713–5719.
54. [54] Gong, J., Chen, D., Kashiwaba, M., Kufe, D., Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3:5 (1997), 558–561.
55. [55] Kalos, M., June, C.H., Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 39:1 (2013), 49–60.
56. [56] Bernal, M., Ruiz-Cabello, F., Concha, A., Paschen, A., Garrido, F., Implication of the beta2-microglobulin gene in the generation of tumor escape phenotypes. Cancer Immunol. Immunother. 61:9 (2012), 1359–1371.
57. [57] Gill, S., Maus, M.V., Porter, D.L., Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev. 30:3 (2016), 157–167.
58. [58] Fousek, K., Ahmed, N., The evolution of T-cell therapies for solid malignancies. Clin. Cancer Res. 21:15 (2015), 3384–3392.
59. [59] Louis, C.U., Savoldo, B., Dotti, G., Pule, M., Yvon, E., Myers, G.D., Rossig, C., Russell, H.V., Diouf, O., Liu, E., et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118:23 (2011), 6050–6056.
60. [60] Ahmed, N., Brawley, V.S., Hegde, M., Robertson, C., Ghazi, A., Gerken, C., Liu, E., Dakhova, O., Ashoori, A., Corder, A., et al. Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J. Clin. Oncol. 33:15 (2015), 1688–1696.
61. [61] Whilding, L.M., Vallath, S., Maher, J., The integrin alphavbeta6: a novel target for CAR T-cell immunotherapy?. Biochem. Soc. Trans. 44:2 (2016), 349–355.
62. [62] La-Beck, N.M., Jean, G.W., Huynh, C., Alzghari, S.K., Lowe, D.B., Immune checkpoint inhibitors: new insights and current place in cancer therapy. Pharmacotherapy 35:10 (2015), 963–976.
63. [63] Greenwald, R.J., Freeman, G.J., Sharpe, A.H., The B7 family revisited. Annu. Rev. Immunol. 23 (2005), 515–548.
64. [64] Rozali, E.N., Hato, S.V., Robinson, B.W., Lake, R.A., Lesterhuis, W.J., Programmed death ligand 2 in cancer-induced immune suppression. Clin. Dev. Immunol., 656340, 2012.
65. [65] Wu, X., Zhang, H., Xing, Q., Cui, J., Li, J., Li, Y., Tan, Y., Wang, S., PD-1(+) CD8(+) T cells are exhausted in tumours and functional in draining lymph nodes of colorectal cancer patients. Br. J. Cancer 111:7 (2014), 1391–1399.
66. [66] Maby, P., Tougeron, D., Hamieh, M., Mlecnik, B., Kora, H., Bindea, G., Angell, H.K., Fredriksen, T., Elie, N., Fauquembergue, E., et al. Correlation between density of CD8 + T-cell infiltrate in microsatellite unstable colorectal cancers and frameshift mutations: a rationale for personalized immunotherapy. Cancer Res. 75:17 (2015), 3446–3455.
67. [67] Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366:26 (2012), 2443–2454.
68. [68] Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366:26 (2012), 2455–2465.
69. [69] Le, D.T., Uram, J.N., Wang, H., Bartlett, B.R., Kemberling, H., Eyring, A.D., Skora, A.D., Luber, B.S., Azad, N.S., Laheru, D., et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372:26 (2015), 2509–2520.
70. [70] Brahmer, J.R., Drake, C.G., Wollner, I., Powderly, J.D., Picus, J., Sharfman, W.H., Stankevich, E., Pons, A., Salay, T.M., McMiller, T.L., et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28:19 (2010), 3167–3175.
71. [71] Lipson, E.J., Sharfman, W.H., Drake, C.G., Wollner, I., Taube, J.M., Anders, R.A., Xu, H., Yao, S., Pons, A., Chen, L., et al. Durable cancer regression off-treatment and effective reinduction therapy with an anti-PD-1 antibody. Clin. Cancer Res. 19:2 (2013), 462–468.
72. [72] Jacobs, J., Smits, E., Lardon, F., Pauwels, P., Deschoolmeester, V., Immune checkpoint modulation in colorectal cancer: what's new and what to expect. J. Immunol. Res., 158038, 2015.
73. [73] Chung, K.Y., Gore, I., Fong, L., Venook, A., Beck, S.B., Dorazio, P., Criscitiello, P.J., Healey, D.I., Huang, B., Gomez-Navarro, J., et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J. Clin. Oncol. 28:21 (2010), 3485–3490.
74. [74] Rowe, J., Cen, P., TroVax in colorectal cancer. Hum. Vaccin. Immunother. 10:11 (2014), 3196–3200.
75. [75] Zumwalt, T.J., Goel, A., Immunotherapy of metastatic colorectal cancer: prevailing challenges and new perspectives. Curr. Color. Cancer Rep. 11:3 (2015), 125–140.
76. [76] Taube, J.M., Klein, A., Brahmer, J.R., Xu, H., Pan, X., Kim, J.H., Chen, L., Pardoll, D.M., Topalian, S.L., Anders, R.A., Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin. Cancer Res. 20:19 (2014), 5064–5074.
77. [77] Llosa, N.J., Cruise, M., Tam, A., Wicks, E.C., Hechenbleikner, E.M., Taube, J.M., Blosser, R.L., Fan, H., Wang, H., Luber, B.S., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5:1 (2015), 43–51.
78. [78] Kakarla, S., Song, X.T., Gottschalk, S., Cancer-associated fibroblasts as targets for immunotherapy. Immunotherapy 4:11 (2012), 1129–1138.
79. [79] Zhang, J., Liu, J., Tumor stroma as targets for cancer therapy. Pharmacol. Ther. 137:2 (2013), 200–215.
80. [80] Lal, N., Beggs, A.D., Willcox, B.E., Middleton, G.W., An immunogenomic stratification of colorectal cancer: implications for development of targeted immunotherapy. Oncoimmunology, 4(3), 2015, e976052.
81. [81] Llosa, N.J., Cruise, M., Tam, A., Wicks, E.C., Hechenbleikner, E.M., Taube, J.M., Blosser, R.L., Fan, H., Wang, H., Luber, B.S., et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov. 5:1 (2015), 43–51.
82. [82] Pardoll, D.M., The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12:4 (2012), 252–264.
83. [83] Lawrence, M.S., Stojanov, P., Polak, P., Kryukov, G.V., Cibulskis, K., Sivachenko, A., Carter, S.L., Stewart, C., Mermel, C.H., Roberts, S.A., et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499:7457 (2013), 214–218.
84. [84] Mellman, I., Hubbard-Lucey, V.M., Tontonoz, M.J., Kalos, M.D., Chen, D.S., Allison, J.P., Drake, C.G., Levitsky, H., Lonberg, N., van der Burg, S.H., et al. De-risking immunotherapy: report of a consensus workshop of the cancer immunotherapy consortium of the Cancer Research Institute. Cancer Immunol. Res. 4:4 (2016), 279–288.
85. [85] Watanabe, T., Hotta, C., Koizumi, S., Miyashita, K., Nakabayashi, J., Kurotaki, D., Sato, G.R., Yamamoto, M., Nakazawa, M., Fujita, H., et al. The transcription factor IRF8 counteracts BCR-ABL to rescue dendritic cell development in chronic myelogenous leukemia. Cancer Res. 73:22 (2013), 6642–6653.